Gilead Sciences Inc (GILD)
Health Care ยท Biological Products, (No Diagnostic Substances)
Gilead Sciences Inc (GILD) is listed on Nasdaq, where its shares have traded since January 22, 1992. SentiSense covers Gilead Sciences Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Daniel O'Day is its chief executive officer. The company reports 17,000 employees, and its corporate website is www.gilead.com.
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Latest reported results
Gilead Sciences, Inc. reported revenue of $8.30 billion for Q3 FY2026, up 6.8% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 2,257 institutions reported holding GILD, with 1.1 billion shares worth $139.0 billion in aggregate. The largest reported holders were Vanguard, BlackRock and FMR.
More on GILD
- GILD sentiment: whether news and social coverage of Gilead Sciences Inc leans bullish or bearish, and the stories driving it.
- GILD ownership: all 2,257 reporting institutions, plus insider and congressional trades.
- GILD financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Gilead Sciences Inc do?
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care.
What sector is GILD in?
SentiSense classifies Gilead Sciences Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does GILD stock trade?
Gilead Sciences Inc (GILD) is listed on Nasdaq, where its shares have traded since January 22, 1992.
Who is the CEO of Gilead Sciences Inc?
Daniel O'Day is the chief executive officer of Gilead Sciences Inc.